Explore the Agenda
8:00 am Morning Coffee & Workshop Check-In
Workshop A
9:00 am Engineering Bispecifics for Solid Tumour Success to Maximise Penetration, Immune Engagement & Translational Impact
Solid tumours represent the next major frontier for bispecific antibody therapeutics, with significant unmet medical need and opportunities to expand efficacy beyond hematologic malignancies. This workshop will explore strategies to overcome the unique challenges of solid tumours, including physical barriers, heterogeneous target expression, and an immunosuppressive tumour microenvironment. Participants will learn to optimise tumour penetration, enhance immune engagement, and leverage preclinical models to anticipate clinical outcomes and accelerate the path from discovery to clinic.
This workshop will gather experts to discuss:
- Understand key barriers to efficacy and learn how physical and immunological features of solid tumours impact bispecific performance
- Enhance tumour penetration and activity by applying cutting-edge engineering strategies and combination approaches to maximise therapeutic impact
- Leverage hematologic learnings for solid tumours and translate proven principles from blood cancer bispecifics to inform solid tumour design
- Predict clinical success with preclinical tools by evaluating models and predictive strategies to anticipate efficacy, optimise dosing, and reduce translational risk
12:00 pm Lunch Break & Networking
Workshop B
1:00 pm The Engineering Advantage: De-Risking Bispecific Antibodies from Concept to Clinic
With bispecifics and T-cell engagers advancing rapidly, early-stage development carries significant translational, immunogenicity, and safety risk. This workshop will explore how to design integrated preclinical packages that better predict human pharmacology, safety, and immune-related liabilities, enabling more confident progression into the clinic. Participants will learn how to align mechanism-of-action, safety, and immunogenicity assessments to build confidence in human outcomes and accelerate early clinical decision-making.
This workshop will gather experts to discuss:
- Optimise biologics for safety, efficacy and immunogenicity to confidently de-risk bispecifics and TCEs before entering clinical studies
- Identify and mitigate immune-related and safety liabilities early, strengthening predictivity and reducing clinical development risk
- Leverage mechanism-of-action insights to integrate safety and immunogenicity considerations into preclinical packages to accelerate regulatory approval and clinic readiness